These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 8744632)

  • 41. [Embolic episodes after treatment of atrial fibrillation in a patient with thyrotoxicosis].
    Hendriksen O; Petersen CL
    Ugeskr Laeger; 1995 Jul; 157(29):4138-9. PubMed ID: 7652995
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Activated protein c resistance (APC) and inherited factor V (FV) mis-sense mutation in patients with venous and arterial thrombosis in a haematology clinic.
    Ma DD; Aboud MR; Williams BG; Isbister JP
    Aust N Z J Med; 1995 Apr; 25(2):151-4. PubMed ID: 7605298
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Prevalence of factor V Leiden mutation and other hereditary thrombophilic factors in Egyptian children with portal vein thrombosis: results of a single-center case-control study.
    El-Karaksy H; El-Koofy N; El-Hawary M; Mostafa A; Aziz M; El-Shabrawi M; Mohsen NA; Kotb M; El-Raziky M; El-Sonoon MA; A-Kader H
    Ann Hematol; 2004 Nov; 83(11):712-5. PubMed ID: 15309526
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Factor V Leiden paradox: risk of deep-vein thrombosis but not of pulmonary embolism.
    Bounameaux H
    Lancet; 2000 Jul; 356(9225):182-3. PubMed ID: 10963193
    [No Abstract]   [Full Text] [Related]  

  • 45. [Significance of atrial fibrillation, left atrial thrombus and severity of stenosis for risk of systemic embolism in patients with mitral stenosis].
    Sanada J; Komaki S; Sannou K; Tokiwa F; Kodera K; Terada H; Harubyu N; Tanaka Y; Arima T
    J Cardiol; 1999 Jan; 33(1):1-5. PubMed ID: 10028455
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Resistance to activated protein C in newborns with necrotizing enterocolitis.
    Göpel W; Christiansen B; Reiss I; Möller J; Gortner L
    Eur J Pediatr; 1999 Jul; 158(7):608. PubMed ID: 10412827
    [No Abstract]   [Full Text] [Related]  

  • 47. First-trimester repeated abortion is not associated with activated protein C resistance.
    Balasch J; Reverter JC; Fábregues F; Tàssies D; Rafel M; Creus M; Vanrell JA
    Hum Reprod; 1997 May; 12(5):1094-7. PubMed ID: 9194672
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cerebral venous thrombosis. Role of activated protein C resistance and factor V gene mutation.
    Brey RL; Coull BM
    Stroke; 1996 Oct; 27(10):1719-20. PubMed ID: 8841316
    [No Abstract]   [Full Text] [Related]  

  • 49. "Pseudo homozygous" activated protein C resistance due to double heterozygous factor V defects (factor V Leiden mutation and type I quantitative factor V defect) associated with thrombosis: report of two cases belonging to two unrelated kindreds.
    Simioni P; Scudeller A; Radossi P; Gavasso S; Girolami B; Tormene D; Girolami A
    Thromb Haemost; 1996 Mar; 75(3):422-6. PubMed ID: 8701401
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Embolic complications in atrial fibrillation. Data of the Studio Italiano Fibrillation Atriale (SIFA)].
    G Chir; 1995 Mar; 16(3):137-9. PubMed ID: 7547128
    [No Abstract]   [Full Text] [Related]  

  • 51. Atrial fibrillation and pulmonary embolism.
    Szwast A; Hanna B; Shah M
    Pediatr Emerg Care; 2007 Nov; 23(11):826-8. PubMed ID: 18007216
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Hypercoagulability in atrial fibrillation and its relationship with risk factors for systemic embolism].
    Pérez LA; Corbalán R; Acevedo M; Pereira J; Braun S; Tapia J; Kramer A; Lira MT; Huete I; Sepúlveda G; Springmüller D
    Rev Med Chil; 2002 Oct; 130(10):1087-94. PubMed ID: 12491825
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Activated protein C resistance: the commonest hereditary hypercoagulation disorder.
    Sulaiman-Shoab S
    Br J Surg; 1998 Aug; 85(8):1161. PubMed ID: 9718029
    [No Abstract]   [Full Text] [Related]  

  • 54. Embolism and atrial fibrillation. A longitudinal follow-up.
    Yipintsoi T; Jirathamopas W; Suntiparpluacha C; Jintapakorn W; Akaravinake A; Kunjara-Na-Ayudhya R
    J Med Assoc Thai; 1992 Feb; 75(2):73-8. PubMed ID: 1645052
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism.
    Rodeghiero F; Tosetto A
    Ann Intern Med; 1999 Apr; 130(8):643-50. PubMed ID: 10215560
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Identification and functional characterization of a novel F5 mutation (Ala512Val, FVB onn ) associated with activated protein C resistance.
    Pezeshkpoor B; Castoldi E; Mahler A; Hanel D; Müller J; Hamedani NS; Biswas A; Oldenburg J; Pavlova A
    J Thromb Haemost; 2016 Jul; 14(7):1353-63. PubMed ID: 27090446
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Asymptomatic atrial fibrillation and stroke risk.
    Ahmad N; Kamal AK
    J Pak Med Assoc; 2014 Mar; 64(3):362. PubMed ID: 24864620
    [No Abstract]   [Full Text] [Related]  

  • 58. Activated protein C resistance caused by a common factor V mutation has a single origin.
    Zöller B; Hillarp A; Dahlbäck B
    Thromb Res; 1997 Feb; 85(3):237-43. PubMed ID: 9058498
    [TBL] [Abstract][Full Text] [Related]  

  • 59. How much atrial fibrillation is too much atrial fibrillation?
    Lamas G
    N Engl J Med; 2012 Jan; 366(2):178-80. PubMed ID: 22236229
    [No Abstract]   [Full Text] [Related]  

  • 60. [Atrial fibrillation. What's new in treatment and prophylaxis of embolic complications?].
    Musiał WJ
    Pol Merkur Lekarski; 1996 Nov; 1(5):351-4. PubMed ID: 9273217
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.